OVID - オ―ビッド・セラピュ―ティクス （Ovid Therapeutics Inc.）

Ovid Therapeutics (NASDAQ: OVID ) reported its Q1 earnings results on Friday, May 5, 2023 at 07:30 AM. Here''s what investors need to know about the announcement. Earnings Ovid Therapeutics missed estimated earnings by 11.76%, reporting an EPS of $-0.19 … Full story available on Benzinga.com

Ovid Therapeutics press release (NASDAQ:OVID): Q1 GAAP EPS of -$0.19 misses by $0.02.Revenue of $0.07M (-95.2% Y/Y) beats by $0.05M.

https://www.investing.com/news/assorted/ovid-therapeutics-announces-longterm-safety--efficacy-findings-from-soticlestat-open-label-extension-study-presented-by-takeda-432SI-3066691

https://www.investing.com/news/pro/ovid-therapeutics-inc-pt-raised-to-250-at-citi-432SI-3031625

According to Benzinga Pro data, during Q4, Ovid Therapeutics (NASDAQ: OVID ) posted sales of $46 thousand. Earnings were up 3.87%, but Ovid Therapeutics still reported an overall loss of $11.50 million. In Q3, Ovid Therapeutics brought in $11 thousand in sales but lost $11.97 million in earnings. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a … Full story available on Benzinga.com

https://www.investing.com/news/pro/ovid-therapeutics-inc-pt-raised-to-250-at-citi-432SI-3031625

According to Benzinga Pro data, during Q4, Ovid Therapeutics (NASDAQ: OVID ) posted sales of $46 thousand. Earnings were up 3.87%, but Ovid Therapeutics still reported an overall loss of $11.50 million. In Q3, Ovid Therapeutics brought in $11 thousand in sales but lost $11.97 million in earnings. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a … Full story available on Benzinga.com

Ovid Therapeutics press release (OVID): Q4 GAAP EPS of -$0.16 beats by $0.02.Cash, cash equivalents and marketable securities as of December 31, 2022 totaled $129.0 million.

NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022.

Ovid Therapeutics Earnings, Revenue Beat in Q3

Ovid Therapeutics Earnings, Revenue Beat in Q3

Ovid Therapeutics press release (OVID): Q3 GAAP EPS of -$0.17 beats by $0.04.Revenue of $11.1K.The company ended Q3 with cash, cash equivalents and marketable securities of…

NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today reported financial results and corporate highlights for the third quarter ended September 30, 2022.

NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will present at the H.C. Wainwright 24 th Annual Global Investment Conference in New York, New York on Monday, September 12, 2022, at 12:00 p.m. ET.

The following slide deck was published by Ovid Therapeutics Inc.